References
- AZIE, N. E., BRATER, D. C., BECKER, P. A., JONES, D. R. and HALL, S. D., 1998, The interaction of diltiazem with lovastatin and pravastatin. Clinical Pharmacology and Therapeutics, 64, 369–377.
- BEAIRD, S. L., 2000, HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. Journal of the American Pharmaceutical Association, 40, 637–644.
- HIRAYAMA, M., YOSHIMURA, Y. and MORIYASU, M., 2000, Carrier-mediated uptake of cerivastatin in primary cultured rat hepatocytes. Xenobiotic Metabolism and Disposition, 15, 219–225.
- KANTOLA, T., KIVISTO, K. T. and NEUVONEN, P. J., 1998, Effect of itraconazole on the pharmacokinetics of atorvastatin. Clinical Pharmacology and Therapeutics, 64, 58–65.
- KOGA, T., FUKUDA, K., SHIMADA, Y., FUKAMI, M., KOIKE, H. and TSUJITA, Y., 1992, Tissue selectivity of pravastatin sodium, lovastain and simvastatin. European Journal of Biochemistry, 209, 315–319.
- KOMAI, T., KAWAI, K., TOKUI, T., TOKUI, Y., KUROIWA, C., SHIGEHARA, E. and TANAKA, M., 1992a, Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. European Journal of Drug Metabolism and Pharmacokinetics, 17, 103–113.
- KOMAI, T., SHIGEHARA, E., TOKUI, T., KOGA, T., ISHIGAMI, M., KUROIWA, C. and HORIUCHI, S., 1992b, Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochemical Pharmacology, 43, 667–670.
- McCoRmicx, A. D., MCKILLOP, D., BUTTERS, C. J., MILES, G. S., BABA, T., TOUCHI, A. and YAMAGUCHI, Y., 2000, ZD4522 — an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. Journal of Clinical Pharmacology, 40, 1055.
- MCTAGGART, F., BUCKETT, L., DAVIDSON, R., HOLDGATE, G., McCoRmicx, A., SCHNECK, D., SMITH, G. and WARWICK, M., 2001, Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. American Journal of Cardiology, 87, 28B–32B.
- MUCK, W., MAI, I., FRITSCHE, L., OCHMANN, K., ROHDE, G., UNGER, S., JOHNE, A., BAUER, S., BUDDE, K., ROOTS, I., NEUMAYER, H. H. and KUHLMANN, J., 1999, Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clinical Pharmacology and Therapeutics, 65, 251–261.
- OHTAWA, M., MASUDA, N., AKASAKA, I., NAKASHIMA, A., OCHIAI, K. and MORIYASU, M., 1999, Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells. British Journal of Clinkal Pharmacology, 47, 383–389.
- OLSSON, A. G., 2001, Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. American Journal of Cardiology, 87, 33B–36B.
- SIRTORI, C. R., 1993, Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmacology and Therapeutics, 60, 431–459.
- TSE, F. L. S., SMITH, H. T., BALLARD, F. H. and NICOLETTI, J., 1990, Disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in mouse, rat, dog, and monkey. Biopharmaceutics and Drug Disposition, 11, 519–531.
- WATANABE, M., KOIKE, H., ISHIBA, T., OKADA, T., SEO, S. and HIRAI, K., 1997, Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole- substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorganic and Medical Chemistry, 5, 437–444.